Mobile

A Phase 2, 12-Week, Randomized, Placebo-Controlled Study to Evaluate the Antiinflammatory Effects of VX-702 when Administered Concomitantly with Methotrexate

Mise à jour : Il y a 4 ans
Référence : EUCTR2006-004715-22

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

*To evaluate the effects of 2 dosing regimens of VX-702 administered with concomitant methotrexate (MTX), and MTX alone, on the concentrations of serum and urinary biomarkers of inflammation and bone resorption. • To evaluate the safety and tolerability of VX-702 administered with concomitant MTX, and MTX alone, when administered for 12 weeks in subjects with moderate to severe rheumatoid arthritis (RA).

Critère d'inclusion

  • Rheumatoid Arthritis

Liens